Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia

Neuropsychobiology

Volumn 62, Issue 2, 2010, Pages 87-90

  Rizos, E N ^a   Michalopoulou, P G ^a,e   Siafakas, N ^a   Stefanis, N ^a   Douzenis, A ^a   Rontos, I ^d   Laskos, E ^b   Kastania, A ^b   Zoumpourlis, V ^c   Lykouras, L ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c INSTITUTE OF BIOLOGY   (Greece)

^d GENERAL HOSPITAL OF NIKEA   (Greece)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Brain derived neurotrophic factor; Duration of untreated psychosis; First episode of schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENETIC ASSOCIATION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; ADULT; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 77952970380     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315438     Document Type: Article

References (32)

1. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389: 856-860.
2. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350: 230-232.
3. Shoval G, Weizman A: The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 2005; 15: 319-329.
4. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberg DR, Kleinman JE: Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8: 592-610.
5. Buckley P, Pillai A, Evans D, Stirewalt E, Mahadick S: Brain-derived neurotrophic factor in first-episode psychosis. Schizophr Res 2007; 91: 1-5.
6. Grillo RW, Ottoni G, Leke R, Souza DO, Portela LV, Lara DR: Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007; 41: 31-35.
7. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F: Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007; 420: 45-48. (Pubitemid 46777098)
8. Rizos EN, Rontos I, Laskos E, Arsenis G, Michalopoulou PG, Vasilopoulos D, et al. Investigation of serum BDNF levels in drugnaïve patients with schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 2008; 32: 1308-1311.
9. Angelucci F, Mathe AA, Aloe L: Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000; 60: 783-794.
10. Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, Vasilopoulos D, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with atypical antipsychotics. World J Biol Psychiatry 2008; 10: 1-5.
11. Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325-351.
12. Lieberman JA, Sheitman BB, Kinon BJ: Endogenous neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997; 17: 205-229.
13. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T: Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975-983.
14. First MB, Spitzer RL, Gibbon M, William JBM: Structured Clinical Interview for DSMIV Axis I Disorders. Patient Edition. New York, Biometrics Research, 1997.
15. Kay SR, Opler LA, Lindenmayer JP: The Positive and Negative Syndrome Scale (PANSS): rational and standardization. Br J Psychiatry 1987; 155(suppl 7):59-65.
16. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. DSM IV. Washington, American Psychiatric Association, 1994.
17. Perkins DO, Gu H, Boteva K, Lieberman JA: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and metaanalysis. Am J Psychiatry 2005; 162: 1785-1804.
18. Wyatt R, Henter I: Rationale for the study of early intervention. Schizophr Res 2001; 51: 69-76.
19. Lee C, Shenton M, Salisbury D, Kasay K, Onitsuka T, Dickey C, Yergelun-Todd D, et al. Fusiform gyrus volume reduction in firstepisode schizophrenia: a magnetic resonance imaging study. Arch Gen Psychiatry 2002; 59: 775-781.
20. Lappin J, Morgan K, Morgan C, Hutchison G, Chitnis X, Sucking J, et al. Gray matter abnormalities associated with duration of untreated psychosis. Schizophr Res 2006; 83: 145-153.
21. Garner B, Berger G, Nicolo J, Mackinnon A, Wood S, Pariante C, et al. Pituitary volume and early treatment response in drug-naïve first-episode psychosis patients. Schizophr Res 2009; 8: 65-71.
22. Walterfang M, Wood A, Reuters D, Wood S, Chen J, Velakoulis D, McGorry P, Pantelis: Corpus callosum size and shape in first-episode affective and schizophrenia-spectrum psychosis. Psychiatry Res 2009; 173: 77-82.
23. Whitford T, Farrow T, Williams L, Gomes L, Brennan J, Harris A: Delusions and dorsomedial frontal cortex volume in first-episode schizophrenia: a voxel-based morphometry study. Psychiatry Res 2009; 172: 175-179.
24. Qiu A, Zhong J, Graham S, Chia M, Sim K: Combined analyses of thalamic volume, shape and white matter integrity in first-episode schizophrenia. Neuroimage 2009; 47: 1163-1171.
25. Mathalon DM, Sullivan EV, Lim KO, Pfefferbaum A: Progressive brain volume changes of the clinical course of schizophrenia in men. Arch Gen Psychiatry 2001; 58: 148-157.
26. Vidal CN, Rapoport JL, Hayashi KM, Geaga JA, Sui Y, McLemore LE, et al. Dynamically spreading frontal and cingulated deficits mapped in adolescents with schizophrenia. Arch Gen Psychiatry 2006; 63: 25-34.
27. Velakoulis D, Wood S, Wong M, McGorry P, Yung A, Phillips L: Hippocampal and amygdale volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006; 63: 139-149.
28. DeLisi LE: Is schizophrenia a lifetime disorder of brain plasticity, growth and aging? Schizophr Res 1997; 23: 119-129.
29. Palomino A, Pinto AG, Aldama A, Gomez C, Mosquera F, Garcia G: Decreased levels of plasma BDNF levels in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006; 86: 321-322.
30. Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, et al. Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuro-Psychopharmacol and Biol Psychiatry 2007; 31: 78-85.
31. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ: Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553-1561.
32. Karege F, Schwald M, Cisse M: Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328:261-264.